MARKET

BASI

BASI

Bioanalyticl Sys
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.48
-0.01
-0.15%
Closed 13:00 11/27 EST
OPEN
6.49
PREV CLOSE
6.49
HIGH
6.49
LOW
6.44
VOLUME
10.45K
TURNOVER
--
52 WEEK HIGH
16.52
52 WEEK LOW
3.050
MARKET CAP
71.21M
P/E (TTM)
-26.8991
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Andrew N. Alexander, DVM, Ph.D., MBA, DABT, Joins Inotiv as Vice President, Pharmacology and Toxicology Operations
WEST LAFAYETTE, Ind., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“Inotiv”, the “Company”, “We” or “Our”), doing business as Inotiv, a leading provider of drug discovery and development services, announced today that Andrew N. Alexander, DVM, Ph.D., MBA, DABT, has joined the Company as Vice President, Pharmacology and Toxicology Operations, effective October 19, 2020. "Andy brings a skillset that will help us grow Inotiv by providing broader expertise to our clients," said Joe Flynn, the Company’s Chief Commercial Officer. "At least as importantly, Andy embraces our core values, especially delivering excellent client experiences. I am excited to work with Andy here at Inotiv."Don Maul, Sr. Vice President of Surgical Models, added, "Andy has a great deal of experience and considerable expertise not only with pharm/tox studies, but also with designing and supporting studies in the medical device sector, with an emphasis on complex infusion studies."Prior to joining Inotiv, Dr. Alexander established a reputation as a leader in contract research organizations where he worked in roles of increasing responsibility for more than a decade, providing scientific expertise and study direction to clients. He then founded his own company, Scientific Business Advisors, which provided scientific and regulatory consulting to biopharmaceutical, veterinary, and medical device companies. His credentials and training include a Doctor of Veterinary Medicine, Ph.D. and MBA, and a postdoctoral fellowship in oncology and immunology, all from or at the University of Wisconsin, as well as a surgical internship at the School of Veterinary Medicine at the University of Illinois.“I am honored to join Inotiv,” said Dr. Alexander. "Being part of a company that is small enough to be flexible and responsive, but large enough to offer a comprehensive suite of services aligns perfectly with my customer service focus."About the CompanyBioanalytical Systems, Inc., operating as Inotiv, is a pharmaceutical discovery and development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. The Company’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit inotivco.com  for more information about the Company.This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the impact of COVID-19 on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.     FOR MORE INFORMATION:Company Contact:  Beth A. Taylor  Chief Financial Officer  Phone: 765.497.8381  btaylor@inotivco.com
GlobeNewswire · 10/20 13:33
BASi to Participate in H.C. Wainright Investment Conference
WEST LAFAYETTE, Ind., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We” or “Our”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced that it will participate in the H.C. Wainright
GlobeNewswire · 09/09 13:33
Is Bioanalytical Systems' (NASDAQ:BASI) 195% Share Price Increase Well Justified?
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a...
Simply Wall St. · 08/21 15:07
Bioanalytical Systems reports Q3 results
Bioanalytical Systems (BASI): Q3 GAAP EPS of -$0.08.Revenue of $15.78M (+45.3% Y/Y)Press Release
Seekingalpha · 08/14 12:39
Bioanalytical Systems Q3 EPS $(0.08) Down From $(0.04) YoY, Sales $15.77M Up From $10.86M YoY
Bioanalytical Systems (NASDAQ:BASI) reported quarterly losses of $(0.08) per share. This is a 100 percent decrease over losses of $(0.04) per share from the same period last year. The company reported $15.77 million in
Benzinga · 08/14 12:37
BASi Releases Earnings for Third Quarter of Fiscal 2020
WEST LAFAYETTE, Ind., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We” or “Our”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced financial results for the three months ended
GlobeNewswire · 08/14 12:33
Insider Buying: The Bioanalytical Systems, Inc. (NASDAQ:BASI) CFO & VP of Finance Just Bought US$59k Worth Of Shares
Simply Wall St. · 05/23 13:34
Bioanalytical Systems reports Q2 results
Bioanalytical Systems (NASDAQ:BASI): Q2 GAAP EPS of -$0.05. Revenue of $16.01M (+71.4% Y/Y) Press Release
seekingalpha · 05/14 17:34
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BASI. Analyze the recent business situations of Bioanalyticl Sys through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Institutional Holdings
Institutions: 26
Institutional Holdings: 1.18M
% Owned: 10.75%
Shares Outstanding: 10.99M
TypeInstitutionsShares
Increased
4
73.64K
New
9
-147.93K
Decreased
4
5.29K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.18%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Director
Gregory Davis
Chairman/Chief Executive Officer/Director
Paul Yonamine
President/Chief Executive Officer/Director
Robert Leasure
President/Director
Agnes Ngo
Chief Financial Officer/Vice President - Finance
Beth Taylor
Vice Chairman/Independent Director
Colbert Matsumoto
Vice President - Operations
Michael Baim
Chief Financial Officer/Executive Vice President/Treasurer
David Morimoto
Executive Vice President/Chief Marketing Officer
Kevin Dahlstrom
Vice President
Andrew Alexander
Vice President
Philip Downing
Executive Vice President
Blenn Fujimoto
Executive Vice President
David Hudson
Vice President
I.M. Grossi
Vice President - Business Development
Connie Dougherty
Executive Vice President
Arnold Martines
Other/Director
John Sagartz
Other
Joe Flynn
Lead Director/Independent Director
Crystal Rose
Other
Joseph Flynn
Independent Director
Christine Camp
Independent Director
Richard Johnson
Independent Director
Earl Fry
Independent Director
R. Matthew Neff
Independent Director
Wayne Kamitaki
Independent Director
Wendy Perrow
Independent Director
Paul Kosasa
Independent Director
Duane Kurisu
Independent Director
Christopher Lutes
Independent Director
Saedene Ota
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BASI
Bioanalytical systems, Inc. is an international contract research company providing drug discovery and development services and analytical instruments. The Company operates in two segments: contract research services and research products. The contract research services segment provides research and development support on a contract basis to pharmaceutical companies. The research products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers, and medical research institutions. The Company supports the preclinical and clinical development needs of researchers and clinicians for small molecule and large biomolecule drug candidates. The contract research services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance and quality control testing.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Bioanalytical Systems, Inc. stock information, including NASDAQ:BASI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BASI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BASI stock methods without spending real money on the virtual paper trading platform.